Organization (Hospital)
Xiangya Hospital of Central South University
ClinicalTrials.gov lists Xiangya Hospital of Central South University as lead sponsor of 170 trials. It has 44 active development programs and 43 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 39 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 50 in 2026 and about 45 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Xiangya Hospital of Central South University: 170 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (257)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Head and Neck Neoplasms | 22 |
| Nasopharyngeal Carcinoma | 16 |
| Nasopharyngeal Neoplasms | 16 |
| Stroke | 14 |
| Dementia | 11 |
Showing 5 of 257 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 39 |
| 2025 | 40 |
| 2024 | 46 |
| 2023 | 27 |
| 2022 | 47 |
| 2021 | 38 |
| 2020 | 35 |
| 2019 | 28 |
| 2018 | 22 |
| 2017 | 23 |
Showing 10 of 21 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 20 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 34 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (44)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Butylphthalide | ST Elevation Myocardial Infarction | Phase 3 | 1 |
| Butylphthalide | Myocardial Infarction | Phase 3 | 1 |
| Edaravone Dexborneol Concentrated Solution for injection | Ischemic Stroke | Phase 3 | 1 |
| Edaravone Dexborneol Concentrated Solution for injection | Stroke | Phase 3 | 1 |
| Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5 | Lung Neoplasms | Phase 2 | 1 |
Showing 5 of 44 active programs.
Approved assets (43)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PROPOFOL | 3 |
| Sufentanil | 3 |
| MIDAZOLAM | 2 |
| MORPHINE | 2 |
| DEXMEDETOMIDINE | 2 |
Showing 5 of 43 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=18) | 40% on time (n=15) |
Journals published in (374)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 34 |
| Blood | 16 |
| The New England journal of medicine | 16 |
| Journal of Alzheimer's disease : JAD | 14 |
| International journal of radiation oncology, biology, physics | 13 |
Showing 5 of 374 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 6 | 6 | 2025-10-07 |
Organization relationships (259)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| West China Hospital | Co sponsors trial with | 25 |
| Nanfang Hospital, Southern Medical University | Co sponsors trial with | 16 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Co sponsors trial with | 13 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Co sponsors trial with | 13 |
| First Affiliated Hospital Zhejiang University | Co sponsors trial with | 12 |
Showing 5 of 259 relationships.
Latest dated events (406)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 406 events.
Biomarker capability evidence (509)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AARS2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ACAD9 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 509 evidence rows.
Biomarkers this organization publishes on (83)
Shown in this order: most publications first.
Showing 5 of 83 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.